C2-8 |
An inhibitor of polyQ aggregation (IC50s = 25 and 0.05 µM for recomb… |
5 mg |
21177-5 |
More Info
|
C29 |
An inhibitor of TLR2 signaling; inhibits synthetic and bacterial TLR2 agon… |
1 mg |
27029-1 |
More Info
|
C29 |
An inhibitor of TLR2 signaling; inhibits synthetic and bacterial TLR2 agon… |
10 mg |
27029-10 |
More Info
|
C29 |
An inhibitor of TLR2 signaling; inhibits synthetic and bacterial TLR2 agon… |
25 mg |
27029-25 |
More Info
|
C29 |
An inhibitor of TLR2 signaling; inhibits synthetic and bacterial TLR2 agon… |
5 mg |
27029-5 |
More Info
|
C3 |
An inhibitor of MAO-B (IC50 = 0.021 µM); selective for MAO-B over MA… |
1 mg |
33166-1 |
More Info
|
C3 |
An inhibitor of MAO-B (IC50 = 0.021 µM); selective for MAO-B over MA… |
10 mg |
33166-10 |
More Info
|
C3 |
An inhibitor of MAO-B (IC50 = 0.021 µM); selective for MAO-B over MA… |
5 mg |
33166-5 |
More Info
|
C527 |
An inhibitor of the USP1 / UAF complex; inhibits USP1 / UAF deubiquitinase… |
10 mg |
21771-10 |
More Info
|
C527 |
An inhibitor of the USP1 / UAF complex; inhibits USP1 / UAF deubiquitinase… |
25 mg |
21771-25 |
More Info
|
C527 |
An inhibitor of the USP1 / UAF complex; inhibits USP1 / UAF deubiquitinase… |
5 mg |
21771-5 |
More Info
|
C527 |
An inhibitor of the USP1 / UAF complex; inhibits USP1 / UAF deubiquitinase… |
50 mg |
21771-50 |
More Info
|
C53 |
A STING agonist; activates human wild-type STING (EC50 = 185 nM), as well… |
1 mg |
37354-1 |
More Info
|
C53 |
A STING agonist; activates human wild-type STING (EC50 = 185 nM), as well… |
10 mg |
37354-10 |
More Info
|
C53 |
A STING agonist; activates human wild-type STING (EC50 = 185 nM), as well… |
5 mg |
37354-5 |
More Info
|
C53 |
A STING agonist; activates human wild-type STING (EC50 = 185 nM), as well… |
50 mg |
37354-50 |
More Info
|
C646 |
An inhibitor of the HAT p300 (IC50 = 1.6 µM); competitively binds p3… |
1 mg |
10549-1 |
More Info
|
C646 |
An inhibitor of the HAT p300 (IC50 = 1.6 µM); competitively binds p3… |
10 mg |
10549-10 |
More Info
|
C646 |
An inhibitor of the HAT p300 (IC50 = 1.6 µM); competitively binds p3… |
5 mg |
10549-5 |
More Info
|
C-7280948 |
A PRMT1 inhibitor (IC50 = 12.8 µM, in vitro) |
1 g |
21601-1 |
More Info
|
C-7280948 |
A PRMT1 inhibitor (IC50 = 12.8 µM, in vitro) |
100 mg |
21601-100 |
More Info
|
C-7280948 |
A PRMT1 inhibitor (IC50 = 12.8 µM, in vitro) |
250 mg |
21601-250 |
More Info
|
C-7280948 |
A PRMT1 inhibitor (IC50 = 12.8 µM, in vitro) |
500 mg |
21601-500 |
More Info
|
C82 |
An Mtb CdnP inhibitor (IC50 = 17.5 µM); selective for Mtb CdnP over… |
1 mg |
33563-1 |
More Info
|
C82 |
An Mtb CdnP inhibitor (IC50 = 17.5 µM); selective for Mtb CdnP over… |
10 mg |
33563-10 |
More Info
|
C82 |
An Mtb CdnP inhibitor (IC50 = 17.5 µM); selective for Mtb CdnP over… |
5 mg |
33563-5 |
More Info
|
C-87 |
An inhibitor of TNF-α; binds to TNF-α; inhibits TNF-α-in… |
10 mg |
36578-10 |
More Info
|
C-87 |
An inhibitor of TNF-α; binds to TNF-α; inhibits TNF-α-in… |
25 mg |
36578-25 |
More Info
|
C-87 |
An inhibitor of TNF-α; binds to TNF-α; inhibits TNF-α-in… |
5 mg |
36578-5 |
More Info
|
C10-200 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
10 mg |
40863-10 |
More Info
|
C10-200 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
25 mg |
40863-25 |
More Info
|
C10-200 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
5 mg |
40863-5 |
More Info
|
C10-200 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
50 mg |
40863-50 |
More Info
|
C3001a |
An activator of K2P2.1 / TREK1 and K2P10.1 / TREK2; increases current ampl… |
1 mg |
31064-1 |
More Info
|
C3001a |
An activator of K2P2.1 / TREK1 and K2P10.1 / TREK2; increases current ampl… |
10 mg |
31064-10 |
More Info
|
C3001a |
An activator of K2P2.1 / TREK1 and K2P10.1 / TREK2; increases current ampl… |
5 mg |
31064-5 |
More Info
|
CA-074 |
A selective cathepsin B inhibitor (Kis = 0.0087, 75, and 233 µM for… |
1 mg |
24679-1 |
More Info
|
CA-074 |
A selective cathepsin B inhibitor (Kis = 0.0087, 75, and 233 µM for… |
500 µg |
24679-500 |
More Info
|
CA-4948 |
An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-typ… |
1 mg |
27598-1 |
More Info
|
CA-4948 |
An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-typ… |
10 mg |
27598-10 |
More Info
|
CA-4948 |
An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-typ… |
25 mg |
27598-25 |
More Info
|
CA-4948 |
An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-typ… |
5 mg |
27598-5 |
More Info
|
CA77.1 |
An inducer of chaperone-mediated autophagy; induces the formation of autop… |
1 mg |
37300-1 |
More Info
|
CA77.1 |
An inducer of chaperone-mediated autophagy; induces the formation of autop… |
10 mg |
37300-10 |
More Info
|
CA77.1 |
An inducer of chaperone-mediated autophagy; induces the formation of autop… |
25 mg |
37300-25 |
More Info
|
CA77.1 |
An inducer of chaperone-mediated autophagy; induces the formation of autop… |
5 mg |
37300-5 |
More Info
|
C14-A1 |
An ionizable cationic lipid; has been used in the generation of LNPs; LNPs… |
1 mg |
40256-1 |
More Info
|
C14-A1 |
An ionizable cationic lipid; has been used in the generation of LNPs; LNPs… |
10 mg |
40256-10 |
More Info
|
C14-A1 |
An ionizable cationic lipid; has been used in the generation of LNPs; LNPs… |
5 mg |
40256-5 |
More Info
|
Cabazitaxel |
A semisynthetic taxane; stabilizes microtubule assembly by reducing lag ti… |
10 mg |
22262-10 |
More Info
|